Nathan D Leedahl
Overview
Explore the profile of Nathan D Leedahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chandra Deb L, McGrath B, Schlosser L, Hewitt A, Schweitzer C, Rotar J, et al.
Open Forum Infect Dis
. 2022 Jul;
9(7):ofac302.
PMID: 35891692
Background: Most antibiotics are prescribed in the ambulatory setting with estimates that up to 50% of use is inappropriate. Understanding factors associated with antibiotic misuse is essential to advancing better...
2.
Roth F, Leedahl N, Leedahl D, Guerrero D
Antibiotics (Basel)
. 2022 Feb;
11(2).
PMID: 35203725
The rapid identification of pathogens that cause bloodstream infections plays a vital role in the modern clinical microbiology laboratory. Despite demonstrating a significant reduction in turnaround time and a significant...
3.
Grindeland J, Grindeland C, Moen C, Leedahl N, Leedahl D
Ann Pharmacother
. 2019 Oct;
54(3):205-212.
PMID: 31578070
There are limited outcomes data for ideal body weight (IBW)-based dosing of intravenous immune globulin (human, IVIG) in hospitalized patients. To investigate clinical outcomes associated with a standardized change from...
4.
McGurran M, Richter L, Leedahl N, Leedahl D
P T
. 2019 Apr;
44(4):185-191.
PMID: 30930603
Purpose: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States. The economic effect of COPD management is substantial, and the prevalence of the...
5.
DeGrote J, Olafson E, Drofa A, Kouznetzov E, Manchak M, Leedahl N, et al.
Can J Hosp Pharm
. 2019 Jan;
71(6):349-355.
PMID: 30626980
Background: Dual antiplatelet therapy with acetylsalicylic acid (ASA) and a P2Y12-receptor antagonist is often used to prevent thrombotic complications after placement of a Pipeline embolization device (PED) for cerebral aneurysm....
6.
Hansen M, Carson P, Leedahl D, Leedahl N
J Manag Care Spec Pharm
. 2018 Feb;
24(2):154-159.
PMID: 29384025
Background: Antimicrobial resistance is a growing concern, and in recent years, there has been increased interest in ambulatory antimicrobial stewardship. Acute rhinosinusitis (ARS) is one of the most common outpatient...
7.
Olafson E, DeGrote J, Drofa A, Kouznetsov E, Manchak M, Leedahl N, et al.
J Pharm Pract
. 2017 Sep;
31(5):519-521.
PMID: 28877643
Purpose: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is often used to prevent thrombotic complications after endovascular stent placement. Most of the published experience surrounding DAPT...
8.
Jones J, Leedahl N, Losing A, Carson P, Leedahl D
J Pharm Pract
. 2017 Mar;
31(2):140-144.
PMID: 28343444
Purpose: Lack of patient follow-up is a major concern during care transitions, and the role of an antimicrobial stewardship program (ASP) in assessing antimicrobial regimens after hospital discharge is not...